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Abstract
Background: MYC is a heterogeneously expressed transcription factor that plays a multifunctional role in many
biological processes such as cell proliferation and differentiation. It is also associated with many types of cancer
including the malignant lymphomas. There are two types of aggressive B-cell lymphoma, namely Burkitt lymphoma
(BL) and a subgroup of diffuse large cell lymphoma (DLBCL), which both carry MYC translocations and overexpress
MYC but both differ significantly in their clinical outcome. In DLBCL, MYC translocations are associated with an
aggressive behavior and poor outcome, whereas MYC-positive BL show a superior outcome.
Methods: To shed light on this phenomenon, we investigated the different modes of actions of MYC in aggressive
B-cell lymphoma cell lines subdivided into three groups: (i) MYC-positive BL, (ii) DLBCL with MYC translocation
(DLBCLpos) and (iii) DLBCL without MYC translocation (DLBCLneg) for control. In order to identify genome-wide
MYC-DNA binding sites a chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-Seq) was
performed. In addition, ChIP-Seq for H3K4me3 was used for determination of genomic regions accessible for
transcriptional activity. These data were supplemented with gene expression data derived from RNA-Seq.
Results: Bioinformatics integration of all data sets revealed different MYC-binding patterns and transcriptional
profiles in MYC-positive BL and DLBCL cell lines indicating different functional roles of MYC for gene regulation in
aggressive B-cell lymphomas. Based on this multi-omics analysis we identified ADGRE5 (alias CD97) - a member of
the EGF-TM7 subfamily of adhesion G protein-coupled receptors - as a MYC target gene, which is specifically expressed
in BL but not in DLBCL regardless of MYC translocation.
Conclusion: Our study describes a diverse genome-wide MYC-DNA binding pattern in BL and DLBCL cell lines with
and without MYC translocations. Furthermore, we identified ADREG5 as a MYC target gene able to discriminate
between BL and DLBCL irrespectively of the presence of MYC breaks in DLBCL. Since ADGRE5 plays an important
role in tumor cell formation, metastasis and invasion, it might also be instrumental to better understand the
different pathobiology of BL and DLBCL and help to explain discrepant clinical characteristics of BL and DLBCL.
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Background
The transcription factor MYC plays a multifunctional role
in many cellular processes such as cell cycle progression,
apoptosis and cellular transformation. Over-expression of
MYC leads to an increased replication activity and is associ-
ated with different types of cancer. This holds also true for
tumors of the immune system especially aggressive B-cell
non-Hodgkin lymphomas (B-NHL) such as Burkitt lymph-
oma (BL) and diffuse large B-cell lymphoma (DLBCL). BL
is an extremely fast growing tumor that carries immuno-
globulin/MYC translocations in almost all cases. The tumor
is predominantly found in male children but may also
occur in adults especially with a compromised immune sys-
tem. Treatment of BL is mainly based on high dose chemo-
therapy with usually favorable clinical outcome [1]. In
contrast, DLBCL rarely carries MYC rearrangements,
which may be associated with both immunoglobulin and
non-immunoglobulin genes. Whereas DLBCL without
MYC translocation reveals long-term survival of 60–70% of
the patients treated with combined immune-chemotherapy,
DLBCL with MYC translocation – regardless of its trans-
location partner – shows a very poor clinical outcome [2–
8]. It is currently unclear why BL and DLBCL with MYC
translocations display this very different clinical course. In
addition, molecular features for a precise stratification of
patients into BL and DLBCL with MYC translocation are
lacking despite the need for different treatment modalities.
To determine the potentially different role of MYC in BL
and DLBCL, we aimed at identifying their molecular fea-
tures by means of chromatin immunoprecipitation com-
bined with high-throughput sequencing (ChIP-Seq) and
whole transcriptome shotgun sequencing (RNA-Seq)
employing B-cell lymphoma cell lines. Validation of the re-
sults was performed with primary lymphoma tissue
samples.
Methods
Cell culture
Three MYC break positive BL cell lines (Blue-1 / ACC-594;
BL-2 / ACC-625 and BL-41 / ACC-160), two MYC break
positive (Carnaval / ACC-724; U2932-R2 / ACC-633) and
two MYC break negative (Karpas-422 ACC-32, U2932-R1 /
ACC-633) DLBCL cell lines (overview Fig. 1a) were ob-
tained in 2012 from the German Collection of Microorgan-
isms and Cell Cultures (DSMZ). The sub-clones U2932-R1
and U2932-R2 were kindly provided by Dr. Quentmeier
(DSMZ, Braunschweig, Germany) [9]. All cell lines were
negatively tested for mycoplasma contamination prior to
use and are currently not listed as cross-contaminated or
misidentified cell lines according the International Cell Line
Authentication Committee (ICLAC). All cell lines were cul-
tivated in RPMI 1640 medium supplemented with Gluta-
MAX™-I (Gibco, Thermo Fisher Scientific) and containing
20% of heat inactivated fetal bovine serum (PAN Biotech,
Aidenbach, Germany) under a humidified atmosphere with
5% CO2 at 37 °C. Cells were thawed and continuously split
3 times per week for a maximum period of three weeks.
Cell counting was performed on a BD Accuri C6 Flow Cyt-
ometer (BD Biosciences, New Jersey, United States) and cell
viability was determined by propidium iodide (PI) – stain-
ing (BD Bioscience, Heidelberg, Germany) according to the
manufacturer’s recommendations. Only cells, which exhib-
ited more than 90% vitality, were used for further
investigation.
Western blotting
1.5 × 106 vital cells were washed three times with PBS and
lysed with protease inhibitors containing RIPA buffer sup-
ported by sonication. After measuring protein concentra-
tion using the BCA protein assay kit (Pierce, Thermo
Fisher Scientific), protein lysates were separated under de-
naturing conditions via gels electrophoresis using 16% so-
dium dodecyl sulfate polyacrylamide gels (Invitrogen,
California, United States) and transferred to Hybond-ECL
nitrocellulose membranes (Amersham Biosciences, New
Jersey, United States) by electroblotting. Membranes were
blocked with a PBST 5% dry milk solution for 1 h followed
by incubation with the respective primary antibody solu-
tion at 4 °C overnight. Subsequently, membranes were
washed three times with PBST and incubated for 1 h with
a secondary antibody conjugated with horseradish perox-
idase (information on primary and secondary antibodies is
available in Additional file 1: Table S1). Chemilumines-
cence was detected using HRP substrate (Luminata Forte,
Merck Chemicals GmbH, Darmstadt, Germany) and
FusionCapt Advance analysis Software (Fusion device, Vil-
ber Lurmat GmBH, Eberhardzell, Germany).
Quantitative real-time PCR analysis
Total RNA was isolated from 1 × 106 vital cells after
washing with PBS employing NucleoSpin RNA Kit
(MACHEREY-NAGEL GmbH & Co. KG, Düren,
Germany). RNA fluorometric quantification was per-
formed by means of the Qubit RNA quantification assay
(Thermo Fisher Scientific). Total RNA was reverse tran-
scribed into complementary DNA (cDNA) using Taq-
Man reverse transcription reagents. Real-time PCR
analysis was realized using TaqMan Real-Time PCR
Master Mix on a Step One Plus Real-Time PCR System
(Thermo Fisher Scientific). All procedures were per-
formed according to the manufacturer’s recommenda-
tions. RT-PCR Taq-Man probes are listed in Additional
file 1: Table S1. Relative RNA expression was calculated
according to the comparative Ct method [10] using the
average expression based on triplicates of two biological
replicates of each cell line. For endogenous control
b2-microglobulin (B2M) or succinate dehydrogenase
complex, subunit A (SDHA) were used.
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ChIP-Seq experiments
Chromatin immunoprecipitation (ChIP) was done
according to published protocols [11, 12] with few modi-
fications. Briefly, 2 × 107 vital cells were fixed for 10 min
at 4 °C in medium containing 1% formaldehyde. After
blocking with 0.1M glycine and washing four times with
PBS, the cells were snap frozen and stored at − 80 °C.
After thawing on ice each cell pellet was resuspended in
5 mL cold LB1 lysis buffer, incubated for 10 min at 4 °C
and for further 10 min ambient temperature in 5 mL
LB2 lysis buffer before being finally dissolved in 3 mL
LB3 buffer. Sonication was performed for 45 min [three
cycles of 15 min each at high power in pulsed mode (30
s on and 30 s off )] using titanium rods combined with a
Bioruptor Sonicator (Diagenode, Seraing, Belgium).
After addition of 300 μL 10% (vol/vol) Triton X-100 and
centrifugation the supernatant was removed, 50 μL of
which were stored as input DNA sample. 1.5 mL of the
supernatant was incubated with 10 μg MYC antibody or
5 μg H3K4me3 antibody at 4 °C overnight. For ChIP
antibody information, refer to Additional file 1: Table S1.
For precipitation of DNA indirectly bound to the re-
spective antibody, 30 μg Dynabeads coupled with Protein
G (Thermo Fisher Scientific) were added for each μg
antibody and incubated for 3 h at 4 °C. Subsequently, the
beads were washed and the immunoprecipitated (IP)
DNA was eluted. Finally, the eluate (input DNA and IP
DNA) was reverse cross-linked overnight at 65 °C
followed by digestion with RNase A and Proteinase K.
The resulting DNA was phenol/chloroform extracted,
precipitated and the DNA was resuspended in 30 μL 10
mM Tris·HCl, pH 8.0. DNA was subjected to
Fig. 1 MYC expression in DLBCL and BL cell lines. a Cell lines categorized according to their genomic MYC status (MYC break). b Quantitative
MYC RNA expression as determined by RT-PCR; endogenous control for normalization: B2M expression. c Western Blot analysis of MYC protein
expression. d Immunohistochemical (IHC) staining for the cellular localization and distribution of MYC protein
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fluorometric quantification by the Qubit DNA quantifi-
cation assay (Thermo Fisher Scientific). Ten ng of
chromatin-immunoprecipitated DNA sample were proc-
essed with NEBNext ChIP-Seq Library Prep Master Mix
Set for Illumina library generation according to the man-
ufacturer’s recommendations. All amplified libraries
were analyzed with the DNA 1000 Kit on the 2100 Bioa-
nalyzer (Agilent, California, United States). Single-read
NGS was done on an Illumina HiSeq 1500 system (50
cycles). Illumina adapters were trimmed from the raw
sequence data and low quality bases and reads were re-
moved with trimmomatic (LEADING:3 TRAILING:3
SLIDINGWINDOW:4:15 MINLEN:36) [13]. Sequence
data was aligned to the main chromosomes of the hu-
man reference genome (GRCh38) with bowtie version
0.12.7 (−e 70 -k 1 -m 1 -n 2 –best) [14]. H3K4 and MYC
peaks were called with MACS2 [15] with a q-value
cut-off of 0.1 and the peaks from the two replicate ChIP
samples were summarized with IDR [16], keeping all
peaks with an IDR < 0.1. Final peaks were annotated to
the nearest transcription start site (TSS) using gene an-
notation from Ensembl release 77. Only peaks with a
maximum distance of 2000 bp to a TSS were kept. Artifi-
cial peaks were removed using the ENCODE blacklist
(https://sites.google.com/site/anshulkundaje/projects/
blacklists). Differential peaks between DLBCL with and
without MYC break and BL were estimated using Diff-
Bind [17] tool.
RNA-Seq analysis
Total RNA was isolated from 1 × 106 lymphoma cells,
which were previously spiked in with 1 × 105 insect cells
(Schneider cells) for data calibration [18]. The quality of
the RNA was determined with an Agilent 4200 TapeSta-
tion and Software A.01.05 (Agilent, California, United
States). 500 ng RNA per sample were processed using
the Illumina TruSeq Stranded mRNA LT Sample Prep
Kit following the manufacturer’s instructions to generate
libraries for RNA sequencing. Samples were sequenced
on a Hi-Seq 4000 (single read mode; length 150 bp)
using the Illumina HiSeq 3000/4000 SBS 150 cycle kit.
Sequence reads were aligned to a concatenated genome
that consisted of the human (GRCh38) and the Drosoph-
ila melanogaster (BDGP5) reference genome, using
STAR alignment tool [19] with default parameters. Gene
annotation from Ensembl release 77 and feature Counts
[20] with default parameters were used to assign read
counts to human and Drosophila genes. Before differen-
tial gene expression analysis, we calculated DESeq2 sam-
ple sizeFactors [21] on the Drosophila gene counts and
applied them to the human sample data. This way, gene
expression levels of the cell lines were calibrated to the
number of sample cells. Then, gene expression levels
were modeled with a generalized linear model assuming
negative binomial distributed data and categorical vari-
ables for the lymphoma type (BL or DLBCL) and MYC
status (MYC break positive or negative). Gene expres-
sion changes were tested for significance with the Wald
test and fold changes with an associated False Discovery
Rate (FDR) below 0.05 were considered significant dif-
ferentially expressed.
Proteomics
The SWATH-MS-based quantification of the proteins
ADGRE5, BYSL and NPM1 was obtained from previously
published data [22]. SWATH-MS measurements were car-
ried out on a TripleTOF 5600+ (Sciex, Darmstadt,
Germany) coupled to an Ultimate 3000 nano-HPLC-system
(Dionex, Idstein, Germany) using an 88min-binary gradi-
ent. The PeakView 2.1 software (Sciex, Darmstadt,
Germany) was employed for quantification of the peptides
based on an in-house library. Only peptides with FDR < 1%
and confidence > 95% were considered for quantification.
Peptide intensities were summed up and normalized to total
protein intensity. Statistical tests were conducted using het-
eroskedastic 1-way ANOVA.
Immunohistochemistry
Immunohistochemical staining was performed using sections
derived from formalin-fixed paraffin-embedded cell line
blocks (n= 12) and primary tissue samples (n= 38). The use
of human primary tissue samples was approved by the Insti-
tutional Review Board of the Charité – Berlin (EA4/104/11).
The immunostaining carried out using the Leica Bond-maX
autostainer (Leica Biosystems, Illinois, United States) accord-
ing to the manufacturer’s protocol. After heat-induced
epitope retrieval, the sections were incubated with
anti-c-myc and anti-CD97 (ADGRE5) rabbit antibodies, re-
spectively (dilution 1:200). Horseradish peroxidase-labeled
Anti-rabbit-IgG using the Bond Polymer Refine Detection
Kit (Leica Biosystems, Illinois, United States) was employed
to convert the chromogen substrate. Staining was performed
with appropriate positive and negative controls.
Results
First, we determined MYC mRNA and MYC protein ex-
pression by qRT-PCR, Western blotting and immunohis-
tochemistry, respectively, in cell lines derived from BL,
DLBCLpos and DLBCLneg patients (Fig. 1 b-d). With
the exception of BL-41, all MYC break positive cell lines
showed high expression of MYC mRNA. The level of
MYC protein expression corresponded without excep-
tion with the presence of MYC breaks. The discrepant
results between MYC RNA and MYC protein expression
in BL-41 might reflect a longer half-life time of the MYC
protein in BL-41 as compared to the other cell lines with
MYC breaks [23–27]. Thus, less RNA is required to gen-
erate high amounts of MYC protein.
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To investigate the MYC DNA-binding capabilities in
BL and DLBCL, we performed MYC ChIP-Seq experi-
ments to determine genome-wide MYC DNA-binding
sites. Additional ChIP-Seq experiments for trimethyla-
tion of histone H3 at lysine 4 (H3K4me3) were carried
out in order to locate genomic areas with open chroma-
tin as indicators for potential transcriptional activity of
nearby genes [28, 29]. To bioinformatically identify dif-
ferential MYC DNA-binding sites the DiffBind package
[17] was employed using a pairwise comparison of the
cell groups (BL vs. DLBCL; BL vs. DLBCLpos; BL vs.
DLBCLneg and DLBCLpos vs. DLBCLneg). Similar dif-
ferential binding analysis was performed with H3K4me3
ChIP-Seq data to ascertain genome wide differential his-
tone patterns and potential active transcriptional sites.
Detailed results of the bioinformatics analyses are avail-
able in Additional file 2: File S2(ChIP-Seq data), while
Figs. 2 and 3 depict aggregated data. The overall number
of MYC DNA-binding sites was higher (approx. 2-fold) in
MYC break positive (BL, DLBCLpos) than MYC break
negative (DLBCLneg) cells (Fig. 2a). Next, we explored
whether genes associated with MYC-binding differed
between the three groups of cell lines. Our data clearly
indicate that there is not only a difference in the number
of genes but in addition, that also different genes are tar-
geted by MYC and/or H3K4 (Fig. 2b). To identify differen-
tial MYC-binding genes we performed a differential peak
analysis comparing four combinations: BL vs. DLBCL, BL
vs. DLBCLneg, DLBCLpos vs. DLBCLneg and BL vs.
DLBCLpos. Cell lines carrying MYC breaks have more
genes located in the vicinity of MYC-binding sites which
leads to a higher number of differential MYC-binding
peaks in relation to MYC break negative cell lines (Fig.
2c). Figure 3 highlights a list of twenty target genes se-
lected that yielded the highest fold changes. The analysis
of the MYC-binding motifs of MYC target genes showed
an interesting distribution (Fig. 2d) with a preference for
non-canonical E-Box motives (approx. 45%), while only
4% carried exclusively the classical canonic E-Box motif
(CACGTG) and 19% both motifs. Strikingly, 32% of iden-
tified MYC targets genes displayed no known
MYC-binding motifs. Non-canonical and/or canonical
E-box was present in approx. 68% of MYC target genes,
thus corroborating previous studies of global mapping of
Fig. 2 Differential binding patterns obtained by ChIP-Seq experiments. a Total gene counts identified by MYC-Chip, H3K4me3-ChIP, and an overlay of MYC/
H3K4me3-ChIP peaks after MACS2 IDR peak calling. b Venn diagrams illustrate the number of identified targets after IDR peak calling of MYC and H3K4 ChIP,
respectively, limited to within 2000 bp from Origin of Replication (ORI). Each count presents a single Ensembl gene ID. c Differential binding analysis between
different lymphoma entities. Each count presents a single Ensembl gene ID, limitation by 2000 bp of ORI, IDR< 0.1 and p-value < 0.05. d Distribution of MYC
E-Box binding motif within the identified genes with differential MYC-Chip peaks
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MYC-binding sites [30]. However, the presence of E-box
motives in the binding loci did not correlate with the
regulation of associated genes [31, 32].
MYC-binding is not the sole factor for activating of
gene expression and associated functional consequences.
In order to gain a deeper insight into the transcriptional
landscape and the impact of the various MYC-binding
patterns, we performed RNA-Seq and correlated the re-
sults with the presence of MYC breaks and with the
MYC and H3K4 binding patterns. In Fig. 4a the number
of genes differentially expressed among the three cell
line groups is given. The highest number of differentially
expressed genes was found between BL and DLBCL in
general, whereby the expression difference between BL
and DLBCLpos was the lowest. This demonstrates that
MYC has a major impact through activation of the same
gene set, which constitutes a significant proportion of
the entire transcriptome. In harmony with this notion,
the comparison of the RNA-Seq data between BL and
DLBCLneg, and DLBCLpos and DLBCLneg revealed
very similar numbers of differentially expressed genes.
This reinforces the similarity in the gene expression
profiles of both types of MYC break positive cell lines.
Lists of differentially expressed genes are given in Add-
itional file 3: File S3(RNA-Seq data). In Fig. 4b some
differentially expressed genes (from Additional file 3: File
S3) are functionally grouped into clustering of differenti-
ation (CD) molecules (B1), integrin molecules (B2) or
MYC-related molecules (B3) and visualized as heat
maps. Most of the identified CD molecules seem to be
upregulated in MYC break positive (BL, DLBCLpos) cell
lines compared to MYC break negative (DLBCLneg) cell
lines.
To validate the data derived from genome-wide
DNA-binding and gene expression, we performed add-
itional gene-specific ChIP (MYC and H3K4me3) and
RT-PCR experiments (Fig. 4c). The selection criteria for
the target genes were MYC DNA-binding according to
ChIP-Seq and differential expression according to
RNA-Seq. Among the identified genes, ZAP-70,
ADGRE5, CDK20, GPAM, SMAD1 and TERT were the
most interesting. Genes lacking differentially expression
such as LARS, FARSA and already described as MYC
target genes like BYSL [33] and NMP1 [34] were
Fig. 3 Selected differentially bound genes derived from MYC and H3K4me3 ChIP-Seq experiments. Twenty selected target genes with a highest
Log Fold Change value obtained from differential binding analysis for each pairwise comparison (BL_vs_DLBCL; BL_vs_DLBCLneg; BL_vs_DLBCLpos;
DLBCLpos_vs_DLBCLneg). Restriction to 2000 bp upstream of transcriptional start site; IDR < 0.1 and p-value < 0.05
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Fig. 4 RNA-Seq and validation of selected targets. a Overview of total counts of identified RNA-Seq targets after differential expression analysis
between pairs of lymphoma (sub-) entities. b Exemplary heatmaps of differentially expressed targets grouped for (B1) clustering of differentiation
molecules, (B2) integrin molecules, and (B3) MYC-related molecules. c Summary of the validation experiment for selected targets via additional
MYC/H3K4me3 ChIP enrichment analysis (C1) and additional TAQ-MAN RT-PCR analyses (C2) in BL (Blue-1; BL-2, BL-41), DLBCLneg (Karpas-422;
U2932-R1) and DLBCLpos (U2932-R2; Carnaval) cell lines (n = 2 biological replicates)
Kleo et al. BMC Cancer          (2019) 19:322 Page 7 of 11
selected as positive control. By independent validation
assays we were able to confirm the data derived from
our ChIP-Seq and RNA-Seq analyses and demonstrate
that a set of genes is able to reliably differentiate be-
tween lymphoma entities.
Interestingly ADGRE5 (previously designated as CD97
and marked by an arrow in Fig. 4, B1) shows strong se-
lective expression in BL cell lines. On the other hand,
some integrin molecules known to be binding partners
of ADGRE5 are downregulated in BL as compared to
DLBCL.
To validated this interesting outcome we quantify the
proteins of ADGRE5 and already known homogeneous
expressed MYC targets like BYSL and NPM1, obtained
from previously published proteomic data [22] (Fig. 5 a)
and western blot analysis (Fig. 5 c). Finally, we demon-
strated the discriminating character of ADGRE5 between
BL and DLBCL in additional immunostainings of cell
lines and FFPE tissue samples (Fig. 5 d).
Discussion
Our RNA-Seq and ChIP-Seq data showed a significant
overrepresentation of ADGRE5 in BL as compared to
DLBCL regardless of the MYC break status of the latter.
This finding was confirmed by independent additional
target-specific ChIP experiments, RT-PCR and
re-analysis of published proteomic data [22] (see Figs. 4
C1-2 and 5 a). For further exploration, we selected
ADGRE5 as an interesting candidate gene. ADGRE5 pre-
viously designated as CD97 [35] belongs to the adhesion
G protein-coupled receptor (GPCR) subfamily E and
was the first receptor of this gene family found to be as-
sociated with cancer [36]. ADGRE5 is a member of the
EGF-TM7 (seven-span transmembrane protein contain-
ing epidermal growth factor domains; Fig. 5 b) protein
family and is constitutively expressed in granulocytes,
monocytes as well as in subsets of T- and B-cells [37–
42]. An increased ADGRE5 expression is found in some
types of leukemia [43–46]. Interestingly, differential ex-
pression of ADGRE5 has also been described for several
solid cancers such as lung, thyroid and colorectal carcin-
omas, indicating a tumor and/or tissue-specific expres-
sion pattern [47–49]. Upregulation of ADGRE5 is often
observed at the invading tumor front as well as in ad-
vanced tumor stages. Furthermore, ADGRE5 presents an
unfavorable prognostic factor [50–54]. Depending on
the cell type and tumor grade, ADGRE5 protein exists in
three isoforms resulting from alternative splicing [55].
Fig. 5 ADGRE5 (alias CD97) protein expression in cell lines and patient tumor samples. a Proteomic analysis of ADGRE5, BYSL and NPM1 level in
BL (i), DLBCLneg (ii) and DLBCLpos (iii) cell lines. b Schematic model of largest ADGRE5 isoform EGF (1,2,3,4,5), Arg-Gly-Asp integrin-binding motif
(RGD), GPCR-autoproteolysis-inducing domain (GAIN), epidermal growth factor domain (EGF), and nucleoside position of potential N-glycosylation
sites are indicated. c Western Blot analysis of expression of ADGRE5, BYSL, NMP1 and endogenous control ß-actin and GAPDH in selected cell
lines. d Immunohistochemical (IHC) staining of ADGRE5 protein in BL, DLBCLpos and DLBCLneg cell lines and FFPE tumor tissue samples. e Overview
of ADGRE5 staining FFPE tumor tissue samples and supplementary information
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ADGRE5 protein is cleaved by self-catalytic proteolysis
into a large extracellular subunit, which contains three
(EGF1,2,5), four (EGF1,2,3,5) or five (EGF1,2,3,4,5)
extracellular N-terminal epidermal growth factor
(EGF)-like domains, that are coupled to the seven-span
transmembrane subunit (TM7) via an extended spacer
region [56–58]. As a surface receptor molecule,
ADGRE5 has the ability to bind ligands of the cellular
and extracellular matrix, enhances proteolytic activity of
matrix metalloproteinases (MMPs) and thus triggers se-
cretion of chemokines [59]. Finally, ADGRE5 interacts
with CD55 [60–63], the glycosaminoglycan chondroitin
sulfate [64, 65], integrin [66] or CD90 [67] in an
isoform-specific manner. Initial functional studies sug-
gest that ADGRE5 is relevant for cell adhesion, migra-
tion and invasion [53, 59, 68].
To determine ADGRE5 isotype distribution in aggres-
sive lymphoma, we performed Western blot analyses
(Fig. 5c) and found that the short isoform (EGF1,2,5) is
homogeneously expressed in all cell lines, while the lar-
gest isoform (EGF1,2,3,4,5) was preferentially present in
BL cell lines. This is a very striking finding, as the
EGF-like repeat 4, which has been reported to interact
with chondroitin sulfate, is only found in the largest
ADGRE5 isoform [64–66]. The interaction of chondro-
itin sulfate and ADGRE5 (EGF4) mediates cell adhesion
and angiogenesis and plays an important role in the
interaction of activated T-cells, dendritic cells and mac-
rophages. This observation fits very nicely to features of
BL, especially angiogenesis and macrophage attraction.
In order to determine the expression profile of
ADGRE5 in primary patient specimens, we performed
immunohistochemical staining (IHC). Figure 5d illus-
trates the higher expression of ADGRE5 on the cell sur-
face of BL cell lines and primary BL patient specimens.
In contrast, primary tissue specimens obtained from
DLBCL patients and cell lines largely lacks ADGRE5
protein expression irrespectively of the presence of MYC
breaks. (Additional IHC staining results are shown in
Additional file 4: Figure S4). Table 5E summarizes the
ADGRE5 IHC results obtained for 38 patients suffering
from BL and DLBCL, respectively. Overall, ADGRE5 is
significantly more frequently positive in BL patients
(88%) as compared to DLBCLs patients that were mainly
negative (80%). Thus, the data derived from our cell line
experiments are nicely reflected in primary patient
specimens.
Conclusion
Here we describe the impact of MYC in three types of ag-
gressive B-cell non-Hodgkin lymphomas: BL and DLBCL
with and without MYC break (DLBCLneg and DLBCLpos,
respectively). More MYC-binding sites were found by
MYC ChIP-Seq in BL and DLBCLpos as compared to
DLBCLneg. Interestingly, MYC was found to be bound to
different target genes in BL and DLBCLpos, which is also
reflected by their gene expression differences. By com-
bined analyses, ADGRE5 (CD97) was identified as an in-
teresting differentially expressed MYC target gene, an
observation confirmed by immunohistochemistry of pri-
mary FFPE patient samples. Its expression, in particular
that of the largest ADGRE5 isoform (EGF1,2,3,4,5), was
significantly higher in BL than DLBCL. Based on the re-
ported function of the EGF4 repeat as a receptor for chon-
droitin sulfate, we hypothesize that this might contribute
to some peculiar features of BL, namely macrophage at-
traction and angiogenesis, and potentially to the very good
responsiveness to treatment. In addition, we suggest
ADGRE5 as a marker to discriminate between BL and
DLBCL (regardless of the presence of MYC breaks) in pa-
tient stratification.
Additional files
Additional file 1: Table S1. Compilation of antibodies used for
Chromatin Immunoprecipitation (ChIP), Western Blot (WB) or
Immunohistochemistry (IHC) and list of TaqMan Assays used for RT-PCR
analysis. *indicated endogenous control. (PDF 42 kb)
Additional file 2: File S2. ChIP-Seq data of differentially bound MYC
and H3K4 target genes derived from comparison of BL vs. DLBCL, BL vs.
DLBCLneg, DLBCLneg vs. DLBCLpos and BL vs. DLBCLpos. (XLSX 1673 kb)
Additional file 3: File S3. RNA-Seq data of differentially expressed
genes derived from comparison of BL vs. DLBCL, BL vs. DLBCLneg,
DLBCLneg vs. DLBCLpos and BL vs. DLBCLpos. (XLSX 13003 kb)
Additional file 4: Figure S4. ADGRE5 IHC staining of cell line and
patient tissue samples. (A) Burkitt Lymphoma (BL): Cell lines (1–5: Blue-1
Bl-41, BL-2, DG-75, CA-46) and primary tumor tissues (7–14) are manly
ADGRE5 positive. (B) Diffuse large B cell lymphoma without MYC break
(DLBCLneg): Cell lines (1–4: Karpass-422, U2932-R1, HT, WSU-DLCL2) and
primary tumor tissues (5–19). (C) DLBCLpos: Cell lines (1–3: Carnaval,
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